JP5940731B2 - Ｓ−アリル−ｌ−システインを有効成分として含む眼疾患予防または治療用組成物、およびこれを含む医薬製剤 - Google Patents

Ｓ−アリル−ｌ−システインを有効成分として含む眼疾患予防または治療用組成物、およびこれを含む医薬製剤 Download PDF

Info

Publication number
JP5940731B2
JP5940731B2 JP2015527392A JP2015527392A JP5940731B2 JP 5940731 B2 JP5940731 B2 JP 5940731B2 JP 2015527392 A JP2015527392 A JP 2015527392A JP 2015527392 A JP2015527392 A JP 2015527392A JP 5940731 B2 JP5940731 B2 JP 5940731B2
Authority
JP
Japan
Prior art keywords
composition
preventing
cysteine
allyl
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015527392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528825A (ja
Inventor
べ キム、ソオン
べ キム、ソオン
ソオン キム、クワン
ソオン キム、クワン
べ キム、ワン
べ キム、ワン
チャン クワク、ウィエ
チャン クワク、ウィエ
トゥク チョン、スン
トゥク チョン、スン
ヤン ヨオン、ヒュン
ヤン ヨオン、ヒュン
ピョ チャン、ヤン
ピョ チャン、ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaking Co Ltd
Original Assignee
Pharmaking Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaking Co Ltd filed Critical Pharmaking Co Ltd
Publication of JP2015528825A publication Critical patent/JP2015528825A/ja
Application granted granted Critical
Publication of JP5940731B2 publication Critical patent/JP5940731B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2015527392A 2012-08-17 2013-08-19 Ｓ−アリル−ｌ−システインを有効成分として含む眼疾患予防または治療用組成物、およびこれを含む医薬製剤 Active JP5940731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020120089857A KR101423631B1 (ko) 2012-08-17 2012-08-17 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
KR10-2012-0089857 2012-08-17
PCT/KR2013/007420 WO2014027865A1 (fr) 2012-08-17 2013-08-19 Composition contenant comme principe actif de la s-allyl-l-cystéine et destinée à prévenir ou à traiter des maladies oculaires, et formulation pharmaceutique contenant cette composition

Publications (2)

Publication Number Publication Date
JP2015528825A JP2015528825A (ja) 2015-10-01
JP5940731B2 true JP5940731B2 (ja) 2016-06-29

Family

ID=50269004

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015527392A Active JP5940731B2 (ja) 2012-08-17 2013-08-19 Ｓ−アリル−ｌ−システインを有効成分として含む眼疾患予防または治療用組成物、およびこれを含む医薬製剤

Country Status (7)

Country Link
US (1) US9326960B2 (fr)
EP (1) EP2886112A4 (fr)
JP (1) JP5940731B2 (fr)
KR (1) KR101423631B1 (fr)
CN (1) CN104540506A (fr)
RU (1) RU2605618C2 (fr)
WO (1) WO2014027865A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2972329T3 (es) * 2015-12-17 2024-06-12 Link Genomics Inc Supresor de neovascularización coroidea o supresor de formación de drusas y método para evaluar o detectar las mismas
TWI715864B (zh) * 2018-09-05 2021-01-11 趙效明 用於預防或治療由視網膜缺血引起的疾病、病症或病況的方法
KR102165845B1 (ko) * 2018-09-18 2020-10-15 안국건강 주식회사 청색광에 의한 눈피로 개선용 조성물
EP3934660A4 (fr) * 2019-03-05 2022-11-23 Cornell University Compositions de matière présentant une activité pour éliminer la lipofuscine de cellules rétiniennes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2875308B2 (ja) 1989-11-22 1999-03-31 湧永製薬株式会社 Ｓ−アリルシステイン高濃度含有組成物の製造方法
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US6866864B2 (en) * 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
WO2002041837A2 (fr) * 2000-11-22 2002-05-30 Rxkinetix, Inc. Traitement de mucosite
WO2005077176A1 (fr) 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Composes anthocyaniniques et procedes d'utilisation correspondants
EP1778207A2 (fr) * 2004-08-18 2007-05-02 Sytera Inc. Compositions combinees avec derives de 13-cis-retinyle et leur utilisation pour le traitement des etats ophtalmiques
DK2110141T3 (da) * 2007-01-31 2013-06-17 Sanwa Kagaku Kenkyusho Co Middel til beskyttelse af retinalnerve eller synsnerve
CN101467991B (zh) * 2007-08-02 2012-02-01 复旦大学 烯丙基半胱氨酸及其类似物在制备治疗心肌损伤药物中的用途
KR101188746B1 (ko) * 2009-09-23 2012-10-11 주식회사파마킹 에스-알릴-엘-시스테인을 유효성분으로 포함하는 위장질환 예방 또는 치료용 조성물
CN102077965A (zh) * 2010-12-14 2011-06-01 吕昌龙 一种制备黑大蒜及从中提取活性物质的方法
CN104415212A (zh) * 2013-08-27 2015-03-18 北京继开德铭医药科技有限公司 大蒜总多糖和含硫氨基酸类的组合物的抗皮肤脱屑及瘙痒用途

Also Published As

Publication number Publication date
WO2014027865A1 (fr) 2014-02-20
KR101423631B1 (ko) 2014-07-25
RU2015107235A (ru) 2016-10-20
US20150231100A1 (en) 2015-08-20
CN104540506A (zh) 2015-04-22
EP2886112A4 (fr) 2015-12-30
EP2886112A1 (fr) 2015-06-24
RU2605618C2 (ru) 2016-12-27
US9326960B2 (en) 2016-05-03
JP2015528825A (ja) 2015-10-01
KR20140023659A (ko) 2014-02-27

Similar Documents

Publication Publication Date Title
KR102188487B1 (ko) 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
US9326957B2 (en) Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
JP5940731B2 (ja) Ｓ−アリル−ｌ−システインを有効成分として含む眼疾患予防または治療用組成物、およびこれを含む医薬製剤
US9849178B2 (en) Combination of carotenoids and epi-lutein
JP7287631B2 (ja) 食品用組成物
WO2014023082A1 (fr) Composition utilisée pour améliorer la densité de pigment maculaire dans les yeux et pour prévenir ou traiter la dégénérescence maculaire liée à l'âge
BRPI0709962A2 (pt) licopeno para o tratamento de disfunção metabólica
JP2007314451A (ja) 糖尿病治療剤
Sarialtin et al. An overview on the role of macular xanthophylls in ocular diseases
WO2021164210A1 (fr) Application d'un dérivé d'acide gallique dans la prévention et le traitement de la maladie de l'athérosclérose
WO2007023774A1 (fr) Agent d’amélioration de la diminution du débit sanguin artériel ophthalmique
JP5860418B2 (ja) クロマメノキ抽出物またはクロマメノキ分画物を有効成分として含む黄斑変性症の治療、予防または改善用組成物
KR102057440B1 (ko) 고삼 추출물 또는 마트린을 포함하는 진정 또는 수면유도용 조성물
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
KR102050506B1 (ko) 망막 질환 예방, 개선, 완화 또는 치료용 조성물
JPWO2018030389A1 (ja) Ｎａｄ関連代謝産物の利用
US20170035708A1 (en) Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide for the treatment of eye diseases
KR20210125259A (ko) 후코스테롤을 유효성분으로 함유하는 난소암 예방 또는 치료용 조성물
KR20100008548A (ko) 클로로겐산을 포함하는 맥락막 혈관신생 관련질환 치료용조성물
US8709515B1 (en) Nutritional supplement method
KR20130046094A (ko) 어저귀 추출물을 포함하는 염증성질환 예방 또는 치료용 의약 조성물
JPWO2019131897A1 (ja) 白内障の予防剤および／または治療剤、白内障の予防および／または治療のための医薬組成物、これらを製造するためのｐｐａｒ活性化剤の使用、ならびに点眼剤
KR20180091415A (ko) 고삼 추출물 또는 마트린을 포함하는 진정 또는 수면유도용 조성물
KR102070305B1 (ko) 아출 추출물을 포함하는 암의 예방 및 치료용 조성물
US20230293482A1 (en) Central nervous system potentiating composition

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160506

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160518

R150 Certificate of patent or registration of utility model

Ref document number: 5940731

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250